About the Authors
- Erika Suzuki
-
Affiliation Onyx Pharmaceuticals, South San Francisco, California, United States of America
- Susan Demo
-
Affiliation Onyx Pharmaceuticals, South San Francisco, California, United States of America
- Edgar Deu
-
Affiliation Stanford University, Stanford, California, United States of America
- Jonathan Keats
-
Affiliation Translational Genomics Research Institute, Phoenix, Arizona, United States of America
- Shirin Arastu-Kapur
-
Affiliation Onyx Pharmaceuticals, South San Francisco, California, United States of America
- P. Leif Bergsagel
-
Affiliation Mayo Clinic, Scottsdale, Arizona, United States of America
- Mark K. Bennett
-
Affiliation Onyx Pharmaceuticals, South San Francisco, California, United States of America
- Christopher J. Kirk
-
* E-mail: ckirk@onyx-pharm.com
Affiliation Onyx Pharmaceuticals, South San Francisco, California, United States of America
Competing Interests
Christopher J. Kirk, Erika Suzuki and Shirin Arastu-Kapur are current employees of Onyx Pharmaceuticals. There are no patents to declare, however this study is in support of the mechanism of action of Carfilzomib, a product currently in development from Onyx. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MKB SD CJK ES SA-K ED JK. Performed the experiments: ES SA-K JK ED SD. Analyzed the data: ES SD JK SA-K MKB CJK. Contributed reagents/materials/analysis tools: PLB MKB CJK. Wrote the paper: SA-K ES CJK JK ED.